Neurotransmitters | Neuroscience

Synaptic Transmission

How neurotransmitters cross the synapse

When an action potential reaches the synaptic terminal, voltage-gated Ca²⁺ channels open → Ca²⁺ enters → synaptic vesicles fuse with the presynaptic membrane → neurotransmitter is released into the synaptic cleft (~20 nm wide) → neurotransmitter diffuses to postsynaptic receptors → receptors activated → postsynaptic effect.

Neurotransmitters exert their effects by binding to one of two types of receptors: ionotropic receptors (ligand-gated ion channels — fast, direct, milliseconds) and metabotropic receptors (G-protein coupled receptors — slow, indirect, seconds to minutes, amplified). The same neurotransmitter can have very different effects depending on which receptor it binds.

💡 Serotonin, Norepinephrine, and Endorphins

Three additional neurotransmitters with major clinical significance: Serotonin (5-HT): Produced mainly in raphe nuclei of the brainstem. Regulates mood, sleep, appetite, thermoregulation, and gut motility (~95% of the body's serotonin is in the gut, not the brain). SSRIs (fluoxetine/Prozac, sertraline/Zoloft) block serotonin reuptake → increased synaptic serotonin → antidepressant effect. Serotonin syndrome (from excess serotonergic activity — SSRI + MAOI, SSRI + tramadol) = triad of mental status changes + autonomic instability + neuromuscular abnormalities (clonus, hyperreflexia). Norepinephrine (NE): Produced in locus coeruleus. Regulates arousal, attention, stress response, and mood. SNRIs (venlafaxine/Effexor, duloxetine/Cymbalta) inhibit both serotonin and NE reuptake. NE also used as vasopressor for shock (norepinephrine/Levophed). Endogenous opioids (endorphins, enkephalins, dynorphins): Bind to μ, δ, and κ opioid receptors. Inhibit pain transmission and produce euphoria. Exogenous opioids (morphine, fentanyl, heroin) mimic endogenous opioids → powerful analgesia and euphoria → high addiction potential. Naloxone (Narcan) = opioid receptor antagonist → reverses overdose.

Glu

Glutamate — the main excitatory neurotransmitter

Glutamate is the primary excitatory neurotransmitter in the CNS — used at roughly 80% of all CNS synapses. It acts on ionotropic receptors (AMPA, NMDA, kainate) and metabotropic receptors (mGluRs). AMPA receptors are the main fast excitatory receptors — they open Na⁺/K⁺ channels and depolarize the postsynaptic cell. NMDA receptors are special — they are both ligand-gated AND voltage-gated (require both glutamate binding AND postsynaptic depolarization to open, because a Mg²⁺ ion blocks the channel at rest). NMDA receptors allow Ca²⁺ entry when both conditions are met — making them molecular coincidence detectors critical for synaptic plasticity (LTP = long-term potentiation) and learning and memory. Excitotoxicity: excessive glutamate release (during stroke or seizure) → massive NMDA receptor activation → Ca²⁺ floods in → activates destructive enzymes → neuron death. NMDA receptor antagonists (ketamine, memantine) protect against excitotoxicity. Memantine is approved for moderate-to-severe Alzheimer's disease.

Memory trick: Glutamate = GAS pedal (excitatory). AMPA = fast excitation (Na⁺ in). NMDA = the learning receptor (needs two keys: glutamate + depolarization). NMDA + Ca²⁺ = long-term potentiation = memory formation.

GABA

GABA — the main inhibitory neurotransmitter

GABA (γ-aminobutyric acid) is the primary inhibitory neurotransmitter in the CNS. It acts on GABA-A receptors (ionotropic — Cl⁻ channels, fast inhibition) and GABA-B receptors (metabotropic — K⁺ channels, slower inhibition). When GABA opens GABA-A Cl⁻ channels → Cl⁻ flows in → membrane hyperpolarizes → further from threshold → less likely to fire = inhibitory postsynaptic potential (IPSP). GABA-A receptors have multiple binding sites — for GABA itself, benzodiazepines, barbiturates, alcohol, and neurosteroids. Benzodiazepines (diazepam/Valium, lorazepam/Ativan) bind to a regulatory site on GABA-A receptors and increase the frequency of Cl⁻ channel opening in response to GABA → enhanced inhibition → anxiolytic, sedative, anticonvulsant effects. Barbiturates (phenobarbital) increase the duration of Cl⁻ channel opening. Alcohol potentiates GABA-A and inhibits NMDA → CNS depression.

Memory trick: GABA = BRAKE pedal (inhibitory). GABA-A = Cl⁻ in = hyperpolarize = stop firing. Benzodiazepines potentiate GABA-A (more Cl⁻). Barbiturates also potentiate GABA-A but more powerfully. Alcohol = GABA-A up + NMDA down.

Dopamine — reward, movement, and psychosis

Dopamine is a catecholamine neurotransmitter with major roles in reward, motivation, motor control, and cognition. Four major dopamine pathways: Mesolimbic pathway (VTA → nucleus accumbens): reward and motivation. Overactivity = positive symptoms of schizophrenia (hallucinations, delusions). All drugs of abuse increase dopamine release here. Mesocortical pathway (VTA → prefrontal cortex): working memory and cognitive function. Underactivity = negative symptoms of schizophrenia (blunted affect, social withdrawal, cognitive deficits). Nigrostriatal pathway (substantia nigra → striatum): motor control. Degeneration = Parkinson's disease → dopamine deficit → resting tremor, rigidity, bradykinesia, postural instability. Tuberoinfundibular pathway (hypothalamus → pituitary): inhibits prolactin release. Dopamine antagonists (antipsychotics) block this → increased prolactin → galactorrhea, amenorrhea. Antipsychotics block D2 dopamine receptors — reducing positive symptoms of schizophrenia but potentially worsening negative symptoms and causing extrapyramidal side effects (drug-induced parkinsonism, tardive dyskinesia).

Memory trick: Dopamine = four pathways. Mesolimbic = reward (overactive = psychosis, drugs of abuse). Nigrostriatal = movement (degenerate = Parkinson's). Mesocortical = thinking. Tuberoinfundibular = prolactin control.

ACh

Acetylcholine — muscle, autonomics, and memory

Acetylcholine (ACh) is the primary neurotransmitter at the neuromuscular junction (NMJ) and in the autonomic nervous system. In the CNS, cholinergic neurons from the basal nucleus of Meynert project to the cortex — these degenerate in Alzheimer's disease → decreased cortical ACh → memory and cognitive deficits. ACh receptors: Nicotinic (ionotropic, Na⁺/K⁺ channels) at NMJ, autonomic ganglia, and CNS. Muscarinic (metabotropic, multiple G-protein effects) in smooth muscle, heart, glands, and CNS. Clinical connections: Myasthenia gravis = autoantibodies against nicotinic ACh receptors at NMJ → reduced ACh signaling → fluctuating muscle weakness. Treatment: acetylcholinesterase inhibitors (pyridostigmine) increase ACh by preventing its breakdown. Alzheimer's disease treatment: donepezil (acetylcholinesterase inhibitor) slows ACh breakdown in cortex — modest symptomatic benefit. Organophosphate pesticides/nerve agents (sarin, VX) inhibit acetylcholinesterase → ACh accumulates → excessive muscarinic (SLUDGE: salivation, lacrimation, urination, defecation, GI upset, emesis) and nicotinic (muscle fasciculations → paralysis) effects.

Memory trick: ACh = NMJ + autonomics + memory. Nicotinic = NMJ + ganglia (fast, ionotropic). Muscarinic = visceral organs (slow, metabotropic). ACh deficiency in cortex = Alzheimer's. Nerve agents block ACh breakdown = SLUDGE + paralysis.

🔬 Clinical Scenario — Neurotransmitters in Psychiatric and Neurological Disease

Every major psychiatric medication targets specific neurotransmitter systems:

Parkinson's disease and dopamine replacement. Loss of dopaminergic neurons in the substantia nigra pars compacta → striatal dopamine deficit → motor symptoms. Treatment: Levodopa (L-DOPA) + carbidopa (prevents peripheral conversion of L-DOPA to dopamine, which cannot cross BBB). L-DOPA crosses BBB and is converted to dopamine in surviving nigrostriatal neurons. As disease progresses and neurons are lost, L-DOPA effectiveness decreases (wearing off, on-off fluctuations). DBS (deep brain stimulation) of the subthalamic nucleus provides additional symptom control.

Schizophrenia — the dopamine hypothesis and beyond. The dopamine hypothesis: mesolimbic dopamine overactivity → positive symptoms (hallucinations, delusions); mesocortical dopamine underactivity → negative symptoms. All effective antipsychotics block D2 receptors. Atypical antipsychotics (clozapine, risperidone, olanzapine) also block 5-HT2A receptors → improved negative symptoms and reduced EPS. Clozapine (most effective antipsychotic) causes agranulocytosis in ~1% → requires weekly CBC monitoring.

Depression — monoamine hypothesis. The monoamine hypothesis of depression: decreased serotonin and/or norepinephrine → depression. Evidence: SSRIs and SNRIs are effective antidepressants. MAOIs (monoamine oxidase inhibitors — phenelzine, tranylcypromine) prevent breakdown of serotonin, NE, and dopamine → increased synaptic levels → antidepressant effect but dangerous interactions with tyramine-containing foods (cheese, wine, cured meats) → hypertensive crisis. Ketamine/esketamine: NMDA receptor antagonist → rapid antidepressant effect within hours (vs weeks for SSRIs) → approved for treatment-resistant depression.

Addiction — dopamine and the reward pathway. All drugs of abuse increase dopamine release in the nucleus accumbens (mesolimbic system). Cocaine and amphetamines block dopamine reuptake (cocaine) or promote dopamine release (amphetamines). Opioids disinhibit dopaminergic VTA neurons. Nicotine stimulates nicotinic ACh receptors on VTA neurons → dopamine release. Alcohol and cannabis → dopamine release. Chronic exposure → receptor downregulation → tolerance → need more drug for same effect → withdrawal when drug stopped (opposing adaptations unmasked).

📌 Exam Application

Neurotransmitter questions are heavily tested in neuroscience, pharmacology, and psychiatry:

1. Glutamate (excitatory): AMPA (fast Na⁺) + NMDA (coincidence detector, Ca²⁺, LTP). Excitotoxicity in stroke/seizure. Memantine (NMDA antagonist) for Alzheimer's.

2. GABA (inhibitory): GABA-A = Cl⁻ in = hyperpolarize. Benzodiazepines potentiate GABA-A (↑ frequency of Cl⁻ opening). Barbiturates (↑ duration). Alcohol = GABA-A up + NMDA down.

3. Dopamine pathways: Mesolimbic = reward/psychosis. Nigrostriatal = movement/Parkinson's. Mesocortical = cognition/negative schizophrenia. Tuberoinfundibular = prolactin.

4. ACh: Nicotinic (NMJ, ganglia). Muscarinic (visceral). MG = anti-nicotinic antibodies. AChE inhibitors = Alzheimer's treatment. Nerve agents = AChE inhibition = SLUDGE.

5. Serotonin: SSRIs = depression. Serotonin syndrome = SSRI + MAOI. 95% in gut.

⚠️ The Most Common Neurotransmitter Mistakes

NMDA receptors require TWO signals to open — not just glutamate. NMDA receptors need both glutamate binding (ligand-gated component) AND postsynaptic depolarization (voltage-gated component — Mg²⁺ block removed by depolarization). This dual requirement makes them coincidence detectors — they only open when the presynaptic and postsynaptic cells are active simultaneously. This is the molecular basis for Hebbian learning ('neurons that fire together wire together'). Students often describe NMDA as simply another glutamate receptor that opens when glutamate binds — missing the critical voltage dependency. Dopamine is BOTH pro-psychotic (mesolimbic) AND essential for movement (nigrostriatal). This creates a fundamental challenge in antipsychotic therapy — blocking D2 receptors to treat psychosis also blocks D2 receptors in the nigrostriatal pathway → extrapyramidal side effects (drug-induced parkinsonism). The goal of atypical antipsychotics (partial D2 agonists, 5-HT2A blockade) is to reduce this motor side effect while maintaining antipsychotic efficacy. SSRIs do NOT immediately increase serotonin levels at clinically relevant synapses. SSRIs block serotonin reuptake immediately — but the clinical antidepressant effect takes 2–4 weeks. The delay reflects receptor downregulation and adaptation: initial SSRI treatment triggers autoreceptor (5-HT1A) desensitization over 2–4 weeks, allowing sustained increased synaptic serotonin to produce clinical effects. This delay is important clinically — patients may feel no benefit initially and may even feel worse (anxiety, suicidality risk in the first 1–2 weeks).

✓ Quick Self-Test

1. What are the two main neurotransmitters of the CNS and what is each's primary function?
2. What makes the NMDA receptor unique among glutamate receptors?
3. Name the four dopamine pathways, their projections, and the disease associated with each.
4. How do benzodiazepines produce their anxiolytic effects at the molecular level?
5. What is the mechanism of organophosphate toxicity?

Answers:
1. Glutamate (primary excitatory): increases probability of postsynaptic firing by opening cation channels (Na⁺/K⁺ via AMPA receptors) or Ca²⁺ channels (NMDA receptors). GABA (primary inhibitory): decreases probability of firing by opening Cl⁻ channels (GABA-A), hyperpolarizing the postsynaptic membrane.
2. NMDA receptors require TWO simultaneous conditions to open: (1) Glutamate (or aspartate) binding to the ligand-binding site AND (2) postsynaptic membrane depolarization (which displaces the Mg²⁺ ion that normally blocks the channel pore at rest). This dual requirement makes NMDA receptors molecular coincidence detectors — they only activate when presynaptic release and postsynaptic depolarization occur simultaneously. Ca²⁺ entry through opened NMDA receptors triggers long-term potentiation (LTP), the cellular basis of learning and memory.
3. Mesolimbic (VTA → nucleus accumbens): reward and motivation; overactivity = positive symptoms of schizophrenia. Mesocortical (VTA → prefrontal cortex): working memory and cognition; underactivity = negative symptoms of schizophrenia. Nigrostriatal (substantia nigra → striatum): motor control; degeneration = Parkinson's disease. Tuberoinfundibular (hypothalamus → anterior pituitary): inhibits prolactin; blockade by antipsychotics = hyperprolactinemia.
4. Benzodiazepines bind to a specific allosteric modulatory site on GABA-A receptors (between the α and γ subunits) — distinct from the GABA binding site. Binding increases the frequency of Cl⁻ channel opening in response to GABA (positive allosteric modulation) without directly opening channels in the absence of GABA. Increased Cl⁻ conductance → hyperpolarization → CNS depression → anxiolysis, sedation, muscle relaxation, anticonvulsant effects.
5. Organophosphates (nerve agents: sarin, VX, tabun; pesticides: malathion, parathion) irreversibly inhibit acetylcholinesterase → ACh cannot be broken down → accumulates at all cholinergic synapses. Muscarinic effects (SLUDGE): salivation, lacrimation, urination, defecation, GI upset, emesis + bradycardia + bronchospasm + miosis. Nicotinic effects: muscle fasciculations → paralysis (including respiratory muscles → death by asphyxia). CNS effects: seizures, coma. Treatment: atropine (muscarinic antagonist) + pralidoxime (reactivates AChE if given early).

Next Lesson

CNS vs PNS

→

← All Neuroscience Lessons